Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis.’ The study aims to evaluate the safety and efficacy of linvoseltamab, an experimental drug, in treating patients whose AL amyloidosis has returned or is unresponsive to other treatments. This research is significant as it explores potential new treatment avenues for a challenging condition.
The intervention being tested is linvoseltamab, a bispecific antibody targeting B-cell maturation antigen and Cluster of Differentiation 3. Its purpose is to improve organ function and manage symptoms in patients with AL amyloidosis.
The study is interventional, with a non-randomized, sequential model in Phase 1, transitioning to a randomized model in Phase 2. There is no masking involved, and the primary aim is treatment-focused.
The study began on February 27, 2024, with primary completion expected by August 26, 2025. The last update was submitted on August 26, 2025, indicating ongoing recruitment and progress.
This clinical update could positively influence Regeneron’s stock performance by showcasing their commitment to innovative treatments. It may also affect investor sentiment favorably, especially if the drug demonstrates promising results. Competitors in the biopharmaceutical sector will be watching closely, as advancements in this area could shift market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.